Cambridge, Massachusetts, USA | 16 November 2026
QurAlis Corporation, a clinical-stage biotechnology company developing precision medicines for neurodegenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for QRL-201, an investigational therapy being developed for Amyotrophic Lateral Sclerosis (ALS). The regulatory milestone allows the company to advance preparations for its planned pivotal CONQUR clinical trial in the United States, with initiation expected in the first half of 2027. Alongside the FDA announcement, QurAlis released final results from the dose-range-finding (DRF) phase of its Phase 1/2 ANQUR clinical trial, reporting encouraging findings on disease progression, neurological biomarkers and treatment tolerability. The development represents an important step in the company’s efforts to advance a potential precision medicine approach for people living with ALS, a progressive neurological condition associated with the degeneration of motor neurons. QRL-201 is designed to address an underlying molecular mechanism associated with ALS rather than simply managing the symptoms of the disease
FDA Clears QRL-201 IND Application for Pivotal ALS Trial
The FDA’s clearance of the QRL-201 IND application represents a significant regulatory milestone for QurAlis, allowing the company to proceed with its planned clinical investigation in the United States. An Investigational New Drug application provides the regulatory framework for administering an investigational medicine to human participants in clinical studies, subject to applicable requirements. QRL-201 is a first-in-class antisense oligonucleotide (ASO) precision therapeutic designed to restore the expression of STATHMIN-2 (STMN2), a protein that plays an important role in neuronal repair, axonal stability and muscle innervation. In many people with ALS, abnormalities involving the TDP-43 protein lead to incorrect processing of STMN2 messenger RNA, resulting in reduced production of functional STATHMIN-2 protein. This reduction may contribute to motor neuron dysfunction and disease progression. By targeting this molecular pathway, QRL-201 aims to restore STMN2 expression and potentially modify the progression of ALS. The investigational therapy is being developed to address both sporadic ALS and relevant genetically associated disease populations. The FDA IND clearance enables the next stage of clinical evaluation but does not represent marketing approval or confirmation of the treatment’s effectiveness.
ANQUR Clinical Trial Reports Encouraging Results
The regulatory announcement was accompanied by final findings from the dose-range-finding phase of the Phase 1/2 ANQUR clinical trial, which evaluated QRL-201 in people living with ALS. The dose-range-finding phase included 52 participants and assessed 3 mg and 10 mg doses against placebo. According to the company, the 10 mg treatment group demonstrated a statistically significant 50% reduction in disease progression compared with placebo, measured using the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R) at Day 253 (p less than 0.05). The lower-dose group also showed evidence of reduced functional decline. In addition to functional assessments, researchers evaluated neurofilament biomarkers associated with nerve cell damage. The 3 mg treatment group demonstrated a 46% reduction in cerebrospinal fluid phosphorylated neurofilament heavy chain (pNfH) from baseline at Day 197 (p less than 0.01). The company also reported reductions in plasma neurofilament light chain (NfL), another biomarker used to assess neurological damage. These biomarker findings provide additional evidence supporting further investigation of the treatment’s biological activity. QurAlis reported that QRL-201 was generally well tolerated during the dose-range-finding phase, with most adverse events classified as mild or moderate and no serious adverse events reported during that phase. The reported clinical and biomarker results are encouraging, although they require confirmation through larger, appropriately controlled clinical studies.
CONQUR Pivotal Trial Planned for First Half of 2027
Following the FDA regulatory milestone and the completion of the dose-range-finding phase, QurAlis is preparing to advance QRL-201 into its planned pivotal CONQUR clinical trial, expected to begin in the first half of 2027 in the United States. The company intends to build on the findings from ANQUR to further evaluate the investigational therapy’s safety, efficacy and potential to modify disease progression. Meanwhile, the ANQUR study has transitioned into its open-label extension (OLE) phase, which is ongoing across clinical research sites in Canada, the United Kingdom and the European Union. The company reported that 41 participants were receiving continued treatment with the 3 mg dose during this extension phase. Open-label extension studies provide an opportunity to collect additional information about longer-term treatment exposure, safety and tolerability. Further details about the planned CONQUR study are expected to be announced in early 2027. The upcoming clinical programme will be important in determining whether the biological and clinical signals observed in earlier research can translate into meaningful and sustained benefits for patients. The progression of QRL-201 into pivotal clinical development highlights the growing role of RNA-targeting technologies and precision medicine in pharmaceutical research for neurodegenerative diseases
Source: QurAlis press release



